American Society of Hirudotherapy

Crystal structure of thrombin in complex with S-variegin: insights of a novel mechanism of inhibition and design of tunable thrombin inhibitors

Research article published in PloS one (2011)

Last Updated: November 1, 2026ASH Editorial · based on the books
Research article — evidence review: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Article reference: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
Evidence: Research reportDrug DevelopmentKoh CY et al. · PloS one, 2011

Abstract

The inhibition of thrombin is one of the important treatments of pathological blood clot formation. Variegin, isolated from the tropical bont tick, is a novel molecule exhibiting a unique 'two-modes' inhibitory property on thrombin active site (competitive before cleavage, noncompetitive after cleavage). For the better understanding of its function, we have determined the crystal structure of the human α-thrombin:synthetic-variegin complex at 2.4 Å resolution. The structure reveals a new mechanism of thrombin inhibition by disrupting the charge relay system. Based on the structure, we have designed 17 variegin variants, differing in potency, kinetics and mechanism of inhibition. The most active variant is about 70 times more potent than the FDA-approved peptidic thrombin inhibitor, hirulog-1/bivalirudin. In vivo antithrombotic effects of the variegin variants correlate well with their in vitro affinities for thrombin. Our results encourage that variegin and the variants show strong potential for the development of tunable anticoagulants.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleResearch Support, Non-U.S. Gov't
Indexed MeSH termsAmino Acid SequenceAnimalsAntithrombinsArthropod ProteinsBinding SitesBiocatalysisCrystallography, X-RayDrug DesignHirudinsHumansKineticsModels, MolecularMolecular Sequence DataMutant ProteinsPeptide FragmentsPeptidesSalivary Proteins and PeptidesStatic ElectricityThrombinZebrafish

Summary

The 2.4 A structure of human alpha-thrombin bound to synthetic variegin, a tick-derived 'two-modes' inhibitor, reveals inhibition by disrupting thrombin's charge relay system; of 17 designed variants, the most active is roughly 70-fold more potent than bivalirudin.

Context

This article describes the 2.4 Å crystal structure of human alpha-thrombin complexed with synthetic variegin, a thrombin inhibitor isolated from the tropical bont tick, and reports the design of 17 variegin variants. The abstract states the most active variant is approximately 70 times more potent than the FDA-approved peptidic thrombin inhibitor hirulog-1/bivalirudin, and that in-vivo antithrombotic effects of the variants correlate with their in-vitro affinities for thrombin. Hirulog-1/bivalirudin is used as a benchmark comparator in the paper and is described as an FDA-approved peptidic thrombin inhibitor. Variegin is tick-derived rather than leech-derived, and the study does not involve hirudotherapy or the leech secretome.

Citation

Reference (Vancouver style)

Koh CY, Kumar S, Kazimirova M, Nuttall PA, Radhakrishnan UP, Kim S, et al. Crystal structure of thrombin in complex with S-variegin: insights of a novel mechanism of inhibition and design of tunable thrombin inhibitors. PLoS One. 2011;6(10):e26367. doi:10.1371/journal.pone.0026367. PMID: 22053189

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 27, 2026 · Site last updated: November 1, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.